Recent Posts
- Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference September 7, 2023
- Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals August 16, 2023
- Eyenovia Announces First Commercial Sale of MydCombi™ August 3, 2023
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com
Eyenovia Announces $15 Million Credit Facility with Avenue Venture Debt Fund
NewsEyenovia announces positive results from VISION-2 Phase 3 Study of MicroLine as a potential on-demand treatment for presbyopia
NewsEyenovia announces planned retirement of Lead Independent Director Ken Lee, Jr.
NewsEyenovia to Participate in Multiple Medical Meetings in September
NewsEYENOVIA ANNOUNCES APPOINTMENT OF OPHTHALMIC INDUSTRY VETERAN MICHAEL ROWE AS CHIEF EXECUTIVE OFFICER AND BOARD MEMBER
NewsEYENOVIA PROVIDES MANUFACTURING UPDATE AND ANNOUNCES APPOINTMENT OF BREN KERN AS SVP OF MANUFACTURING AND OPERATIONS
NewsEYENOVIA ANNOUNCES APPOINTMENTS OF DR. ELLEN STRAHLMAN AND DR. RAM PALANKI AS NEW AND INDEPENDENT MEMBERS OF ITS BOARD OF DIRECTORS
NewsEyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
NewsEyenovia Announces Poster Presentation at the 2022 American Society of Cataract and Refractive Surgery Annual Meeting
NewsEyenovia Announces Positive Study Results Demonstrating that its Optejet® Delivery Technology Reduces Conjunctival Cell Toxicity from Preserved Ophthalmic Solutions to a Level Comparable with Non-Preserved Solutions
News